Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.

How Much Will The Glycomic Therapeutics Market Be Worth By 2029?

In the past few years, there has been a swift expansion in the glycomic therapeutics market size. It is projected to rise from $164.71 billion in 2024 to $189.51 billion in 2025, reflecting a compound annual growth rate (CAGR) of 15.1%. The escalation during the historical period can be traced back to a heightened consciousness about the importance of glycan, the upsurge in chronic diseases, advancement in treatment for rare diseases, and partnerships in the domain of glycomics research.

In the coming years, the market for glycomic therapeutics is projected to undergo swift expansion. It’s anticipated to increase to $359.62 billion in 2029, with a compound annual growth rate (CAGR) of 17.4%. The predicted growth during this forecast period can be credited to factors like the broadening knowledge in glycan biology, the implementation of precision medicine, heightened focus on immunotherapy, substantial funding towards researching rare diseases, and the arrival of glycan biomarkers. Key trends we can expect to witness in this predicted period include the utilization of glycomic applications in the area of oncology, glycoengineering to improve therapeutic proteins, the incorporation of glycomics into immuno-oncology, usage of glycomics in tackling rare and genetic disorders, and the regulatory factors pertaining to glycomic medications.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=11894&type=smp

What Market Forces Are Contributing To The Growth Of The Glycomic Therapeutics Market?

The anticipated rise in diabetes cases is predicted to stimulate expansion in the glycomic therapeutics market. Diabetes, a lasting health disorder impacting the body’s control over blood sugar (glucose) levels, entails changes in glycans that can lead to insulin resistance and distinct metabolic anomalies. Identifiable glycan patterns act as markers for diagnosing diabetes, forecasting its advance, and tracking responses to treatments. For example, in March 2022, the IDF Diabetes Atlas, a globally recognized resource based in Belgium offering extensive data on diabetes prevalence, foresees that the worldwide occurrence of diabetes will grow from 643 million in 2030 to 783 million by 2045, with an increase of 140 million cases. Therefore, it is the rising prevalence of diabetes that fuels the growth of the glycomic therapeutics market.

Which Segments Define The Structure Of The Glycomic Therapeutics Market?

The glycomic therapeuticsmarket covered in this report is segmented –

1) By Class: Isolated; Synthetic

2) By Structures: Glycoproteins; Targeting Sialic Acid; Proteoglycans; Targeting Glycosaminoglycans; Glycosylphosphatidylinositol (GPI)-Anchored Proteins And Heparin Based Glycans; Targeting Glycosphingolipids; Other Structures

3) By Mode Of Action: Inhibits Neuraminidase; Inhibits Heparanase And Selectins And Blocks Interactions Between Growth Factors And Heparan Sulfate; Erythropoietin And Enzyme Replacement Therapy (ERT); Tissue Plasminogen Activator; Inhibits Glucosylceramide Synthase; Interleukin 1, 2 And 3; Beta And Gamma Interferons; Other Mode Of Action

4) By Indications: Thrombosis And Chemoprophylaxis; Anemia; Anti-Adhesive And Anti-Inflammatory; Cataracts; Gaucher’s Disease; Mps-1 And IV; Cancer; Alzheimer’s Disease; Influenza Type A And B; Other Indications

Subsegments:

1) By Isolated: Natural Glycans; Glycan Derivatives; Glycoproteins

2) By Synthetic: Chemically Synthesized Glycans; Recombinant Glycans; Glycopeptides

Which Long-Term Trends Will Play A Crucial Role In The Glycomic Therapeutics Market?

The trend of product innovation is increasingly becoming an important aspect in the glycomic therapeutics market. To secure their market position, main companies involved in the glycomic therapeutics realm are focusing their energies on the creation of innovative and technologically advanced solutions. An example of this can be seen with Glenmark Pharmaceuticals Limited. This pharmaceutical company, based in India, is known for its developments in cutting-edge therapies. In April 2022, they introduced a novel fixed-dose combination (FDC) of a DPP4 inhibitor known as Teneligliptin together with Pioglitazone. Aimed at enhancing glycemic management and minimizing insulin resistance, this combination is specifically targeted at individuals suffering from type 2 diabetes.

Which Firms Are Making The Biggest Impact In The Glycomic Therapeutics Market?

Major companies operating in the glycomic therapeutics market include F Hoffmann-La Roche Ltd., Bayer AG, Sanofi SA, Thermo Fisher Scientific Inc., GlaxoSmithKline plc, Merck KGaA, ICON plc, Agilent Technologies Inc., AMS Bio, Shimadzu Corporation, Waters Corporation, Bruker Corporation, BioMarin Pharmaceutical Inc., Bio Techne Corp., Promega Corporation, Halozyme Therapeutics Inc., Takara Bio Inc., Vector Laboratories, New England Biolabs Inc., Protalix Biotherapeutics Inc., Genovis AB, Ray Biotech Life Inc., IEC Group, Ludger Ltd, Z Biotech LLC, Alzheon Inc., GlycoMar Limited

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/glycomic-therapeutics-global-market-report

Which Region Is Forecasted To Lead The Glycomic Therapeutics Market In The Coming Years?

North America was the largest region in the glycomic therapeutics in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the glycomic therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=11894&type=smp

Browse Through More Reports Similar to the Global Glycomic Therapeutics Market 2025, By The Business Research Company

Blood Cancer Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/blood-cancer-drugs-global-market-report

Cancer Biologics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/cancer-biologics-global-market-report

Rituximab Biosimilar Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/rituximab-biosimilar-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model